Workflow
ChromaDex(CDXC)
icon
Search documents
ChromaDex(CDXC) - 2022 Q4 - Earnings Call Transcript
2023-03-09 02:42
ChromaDex Corporation (NASDAQ:CDXC) Q4 2022 Earnings Conference Call March 8, 2023 4:30 PM ET Company Participants Tom Shumaker – LifeSci Advisors, Agency IR Counsel Rob Fried – Chief Executive Officer Brianna Gerber – Chief Financial Officer Andrew Shao – Senior Vice President-Scientific and Regulatory Affairs Conference Call Participants Mitch Pinheiro – Sturdivant Jeff Van Sinderen – B. Riley Ram Selvaraju – H.C. Wainwright Destiny Hance – Ladenburg Thalmann Sean McGowan – Roth MKM Bill Dezellem – Tieton ...
ChromaDex(CDXC) - 2022 Q4 - Annual Report
2023-03-07 16:00
Ingredients Segment Analytical Reference Standards and Services Segment According to data from Global Wellness Institute, the global wellness industry market was approximately $4.4 trillion in 2020 amidst the disruptions of COVID-19, which is down from $4.9 trillion in 2019. In 2020, the personal care, beauty and anti-aging market was approximately $960 billion, healthy eating, nutrition and weight loss was approximately $950 billion and traditional and complementary medicine market was approximately $410 b ...
ChromaDex(CDXC) - 2022 Q3 - Earnings Call Transcript
2022-11-03 03:52
ChromaDex Corporation (NASDAQ:CDXC) Q3 2022 Earnings Conference Call November 2, 2022 4:30 PM ET Company Participants Tom Shumaker - Investor Relations Robert Fried - Chief Executive Officer Brianna Gerber - Interim Chief Financial Officer Conference Call Participants Jeff Cohen - Ladenburg Thalmann Sean McGowan - ROTH Capital Jeff Van Sinderen - B. Riley Mitchell Pinheiro - Sturdivant & Company Brian Nagel - Oppenheimer Operator Ladies and gentlemen, thank you for standing by, and welcome to ChromaDex Corp ...
ChromaDex(CDXC) - 2022 Q3 - Quarterly Report
2022-11-01 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 Commission File Number: 001-37752 CHROMADEX CORPORATION (Exact Name of Registrant as Specified in its Charter) | --- | --- | --- | |----------------------------------------------------------------------------------|----------------------------|---------------------------------------------- ...
ChromaDex(CDXC) - 2022 Q2 - Earnings Call Transcript
2022-08-11 02:59
ChromaDex Corporation (NASDAQ:CDXC) Q2 2022 Results Conference Call August 10, 2022 4:30 AM ET Company Participants Heather Van Blarcom - Senior Vice President of Legal and Corporate Secretary Robert Fried - Chief Executive Officer Kevin Farr - Chief Financial Officer Brianna Gerber - Vice President of Finance and Investor Relations Conference Call Participants Brian Nagel - Oppenheimer Mitchell Pinheiro - Sturdivant Raghuram Selvaraju - H.C. Wainwright Sean McGowan - ROTH Capital Jeffrey Cohen - Ladenburg ...
ChromaDex(CDXC) - 2022 Q2 - Quarterly Report
2022-08-09 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 Commission File Number: 001-37752 CHROMADEX CORPORATION (Exact Name of Registrant as Specified in its Charter) | --- | --- | --- | |----------------------------------------------------------------------------------|----------------------------|--------------------------------------------------- ...
ChromaDex(CDXC) - 2022 Q1 - Earnings Call Presentation
2022-05-13 12:51
| --- | --- | |--------------------------|-------| | | | | ChromaDex | | | | | | | | | | | | Earnings Conference Call | | | | | | First Quarter 2022 | | Rob Fried Chief Executive Officer Frank Jaksch Co-Founder / Executive Chairman Kevin Farr Chief Financial Officer Nasdaq: CDXC | May 2022 SAFE HARBOR STATEMENT 2 This presentation and other written or oral statements made from time to time by representatives of ChromaDex contain "forward-looking statements" within the meaning of Section 27A of the Securitie ...
ChromaDex(CDXC) - 2022 Q1 - Earnings Call Transcript
2022-05-13 00:53
ChromaDex Corporation (NASDAQ:CDXC) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Rob Fried – Chief Executive Officer Kevin Farr – Chief Financial Officer Brianna Gerber – Vice President of Finance, Investor Relation Frank Jaksch – Co-Founder and Executive Chairman Conference Call Participants Brian W. Nagel – Oppenheimer & Co. Mitchell Pinheiro – Sturdivant & Co. Sean McGowan – ROTH Capital Partners Bill Dezellem – Tieton Capital Management Operator Ladies and gentlemen, tha ...
ChromaDex(CDXC) - 2022 Q1 - Quarterly Report
2022-05-11 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 Commission File Number: 001-37752 CHROMADEX CORPORATION (Exact Name of Registrant as Specified in its Charter) | --- | --- | --- | |----------------------------------------------------------------------------------|----------------------------|-------------------------------------------------- ...
ChromaDex(CDXC) - 2021 Q4 - Annual Report
2022-03-13 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to . Commission file number 001-37752 CHROMADEX CORPORATION (Exact name of Registrant as specified in its Charter) Delaware 26-2940963 (State or other jurisdiction of incorp ...